Urban lifestyles expose the skin to a sustained mix of indoor and outdoor pollutants that drive chronic low-grade inflammation, barrier dysfunction and immune hyperreactivity, producing sensitive, reactive skin. Conventional soothing strategies relieve symptoms without addressing the underlying immune dysregulation. This paper introduces the concept of a cosmetic tolerogen (an active that re-educates the skin’s immune system to restore tolerance instead of suppressing it) and evaluates Toleroxyl™, a recombinant human GM-CSF produced in a plant biofactory. 

Biological activity was assessed in a reconstructed human epidermis model containing Langerhans cells exposed to a standardised Indoor Pollution Challenge. Inflammatory markers, tolerogenic mediators and barrier proteins were quantified and benchmarked against dexamethasone. Efficacy was confirmed in two independent, randomised, double-blind, placebo-controlled clinical studies in volunteers with hyperreactive skin. 

In vitro, the active normalised pollution-induced inflammatory markers, enhanced the tolerogenic factors RELB, SOX4 and TGF-β, and restored barrier proteins. In vivo, it reduced skin redness by up to 65.3 %, improved dermatologist-assessed erythema and functional signs, and lowered pro-inflammatory cytokines. 

By re-educating Langerhans cells towards tolerance, the active restores immune balance, barrier function and visible comfort, defining a new immunomodulatory category for sensitive-skin care.